• On 27 June 2026, Option Care Health, Inc. was added to multiple Russell value and small-cap indices, including the Russell 2000 Value, Russell 2500 Value, Russell 3000 Value, Russell 3000E Value, and Russell Small Cap Comp Value benchmarks, while being removed from the Russell 2000 Dynamic Index.
• This broad index inclusion increases the company’s visibility among institutional investors and index-tracking funds, potentially influencing trading volumes and liquidity given the breadth of these benchmarks.
• With Option Care Health now included across several Russell value and small-cap indices, we’ll assess how this expanded index presence shapes its investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Option Care Health Investment Narrative Recap

To own Option Care Health, you need to believe in the long term shift toward lower cost home and alternate site infusion, supported by payer and pharma partnerships and technology driven efficiencies. The expanded inclusion in multiple Russell value and small cap indices mainly affects trading visibility and liquidity, and does not materially change the near term balance between growth catalysts and key risks such as reimbursement pressure and therapy mix shifts.

Among recent announcements, the expanded US$1,000 million share repurchase authorization stands out next to the index changes. For investors, this capital allocation stance sits alongside the Russell index additions as another factor that can influence how the market values Option Care Health while it works through margin pressure, payer dynamics and the impact of therapy mix, all of which sit at the core of the current investment case.

Yet beneath the broader home infusion growth story, investors should be aware of how reimbursement renegotiations or policy changes could...

Option Care Health's narrative projects $6.8 billion revenue and $298.2 million earnings by 2029. This requires 6.4% yearly revenue growth and about a $92 million earnings increase from $206.2 million today.

Uncover how Option Care Health's forecasts yield a $28.58 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenues of about US$6.9 billion and earnings near US$306 million by 2029, which is a much more upbeat view than the baseline narrative built around therapy mix and reimbursement risks. As the latest Russell index moves play out alongside concerns about chronic therapy resets, it will be important for you to weigh how these different expectations might shift in light of new information.

Explore 2 other fair value estimates on Option Care Health - why the stock might be worth just $24.30!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Option Care Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Option Care Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Option Care Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 43 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.